The risk minimisation materials for belzutifan were developed as a condition of the marketing authorisation grant for this product. The patient alert card should be issued to and carried by patients being treated with belzutifan and provides important safety information to minimise the risk of hypoxia related adverse events. In addition it contains emergency contact details for the patient and their specialist.